Cytomx Thera (CTMX)

$0.71 -0.06 (-7.29%)
Market Cap 61.34M
Revenue (ttm) 138.10M
Net Income (ttm) 31.87M
EPS (ttm) N/A
PE Ratio 1.94
Forward PE 2.28
Profit Margin 23.08%
Debt to Equity Ratio 0.00
Volume 717,600
Avg Vol 2,088,240
Day's Range N/A - N/A
Shares Out 80.10M
Stochastic %K 72%
Beta 1.34
Analysts Strong Sell
Price Target $4.54

Latest News on CTMX

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 6:34 PM EST - 7 weeks ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 6, 2025, 4:10 PM EST - 7 weeks ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 8:00 AM EST - 7 weeks ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 8:00 AM EST - 2 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Jan 6, 2025, 4:05 PM EST - 3 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 5 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:44 AM EST - 6 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:10 PM EST - 6 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Sep 9, 2024, 8:00 AM EDT - 8 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:10 PM EDT - 9 months ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 18, 2024, 8:00 AM EDT - 11 months ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

Jun 17, 2024, 4:15 PM EDT - 11 months ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics Announces New Employment Inducement Grants

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

CytomX stock down 30% despite encouraging cancer study results

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 6:39 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 11, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Mar 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Feb 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Jan 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 21, 2023, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 2:32 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:15 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 31, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

Oct 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

Oct 18, 2023, 4:30 PM EDT - 1 year ago

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Sep 5, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 10, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 10:57 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

Aug 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

Jul 17, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

Jun 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 4:05 PM EDT - 2 years ago

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

May 9, 2023, 11:13 PM EDT - 2 years ago

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023, 4:15 PM EDT - 2 years ago

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

May 1, 2023, 4:01 PM EDT - 2 years ago

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Apr 25, 2023, 4:05 PM EDT - 2 years ago

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ